Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
Identifieur interne : 000404 ( France/Analysis ); précédent : 000403; suivant : 000405Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
Auteurs : Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Chirurgie.
English descriptors
- KwdEn :
- Amantadine, Amantadine (therapeutic use), Amine oxidase (flavin-containing), Antiparkinson Agents (therapeutic use), Apomorphine (therapeutic use), Benzophenones (therapeutic use), Benzothiazoles, Bromocriptine (therapeutic use), COMT inhibitors, Catechol O-Methyltransferase Inhibitors, Deep Brain Stimulation (methods), Deep brain stimulation, Dihydroergocryptine (therapeutic use), Dopamine agonist, Ergolines (therapeutic use), Evidence-based medicine, Fetal Tissue Transplantation (methods), Globus Pallidus (surgery), Humans, Indans (therapeutic use), Indoles (therapeutic use), Levodopa, Levodopa (therapeutic use), Lisuride (therapeutic use), Mesencephalon (cytology), Mesencephalon (embryology), Monoamine Oxidase Inhibitors (therapeutic use), Nervous system diseases, Neurosurgical Procedures (methods), Nitrophenols (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (surgery), Parkinson disease, Parkinson's disease, Pergolide (therapeutic use), Piribedil (therapeutic use), Selegiline (therapeutic use), Surgery, Thiazoles (therapeutic use), Treatment, amantadine, anticholinergics, deep brain stimulation, dopamine agonists, evidence‐based medicine, levodopa, monoamine oxidase inhibitors, neurosurgery, neurotransplantation.
- MESH :
- chemical , therapeutic use : Amantadine, Antiparkinson Agents, Apomorphine, Benzophenones, Bromocriptine, Dihydroergocryptine, Ergolines, Indans, Indoles, Levodopa, Lisuride, Monoamine Oxidase Inhibitors, Nitrophenols, Pergolide, Piribedil, Selegiline, Thiazoles.
- chemical : Benzothiazoles, Catechol O-Methyltransferase Inhibitors.
- cytology : Mesencephalon.
- drug therapy : Parkinson Disease.
- embryology : Mesencephalon.
- methods : Deep Brain Stimulation, Fetal Tissue Transplantation, Neurosurgical Procedures.
- surgery : Globus Pallidus, Parkinson Disease.
- Humans.
Abstract
The objective of this study is to update a previous evidence‐based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001–January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non‐Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty‐seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non‐ efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non‐efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy‐based reviews is essential. We consider a 3‐year period a reasonable time frame for published updates and are working to establish a Web‐based mechanism to update the report in an ongoing manner. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20464
Affiliations:
- Autriche, France, Portugal, États-Unis
- Illinois, Midi-Pyrénées, Tyrol (Land)
- Innsbruck, Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse, Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000137
- to stream Istex, to step Curation: 000137
- to stream Istex, to step Checkpoint: 002334
- to stream PubMed, to step Corpus: 003084
- to stream PubMed, to step Curation: 003084
- to stream PubMed, to step Checkpoint: 003137
- to stream Ncbi, to step Merge: 001217
- to stream Ncbi, to step Curation: 001217
- to stream Ncbi, to step Checkpoint: 001217
- to stream Main, to step Merge: 005011
- to stream PascalFrancis, to step Corpus: 001E94
- to stream PascalFrancis, to step Curation: 000E27
- to stream PascalFrancis, to step Checkpoint: 001E53
- to stream Main, to step Merge: 005331
- to stream Main, to step Curation: 003924
- to stream Main, to step Exploration: 003924
- to stream France, to step Extraction: 000404
Links to Exploration step
ISTEX:44383AF5586D45FB307F9631FBBDF0A5850E2639Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:44383AF5586D45FB307F9631FBBDF0A5850E2639</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20464</idno><idno type="url">https://api.istex.fr/document/44383AF5586D45FB307F9631FBBDF0A5850E2639/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000137</idno><idno type="wicri:Area/Istex/Curation">000137</idno><idno type="wicri:Area/Istex/Checkpoint">002334</idno><idno type="wicri:doubleKey">0885-3185:2005:Goetz C:evidence:based:medical</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15818599</idno><idno type="wicri:Area/PubMed/Corpus">003084</idno><idno type="wicri:Area/PubMed/Curation">003084</idno><idno type="wicri:Area/PubMed/Checkpoint">003137</idno><idno type="wicri:Area/Ncbi/Merge">001217</idno><idno type="wicri:Area/Ncbi/Curation">001217</idno><idno type="wicri:Area/Ncbi/Checkpoint">001217</idno><idno type="wicri:doubleKey">0885-3185:2005:Goetz C:evidence:based:medical</idno><idno type="wicri:Area/Main/Merge">005011</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0281338</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E94</idno><idno type="wicri:Area/PascalFrancis/Curation">000E27</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001E53</idno><idno type="wicri:doubleKey">0885-3185:2005:Goetz C:evidence:based:medical</idno><idno type="wicri:Area/Main/Merge">005331</idno><idno type="wicri:Area/Main/Curation">003924</idno><idno type="wicri:Area/Main/Exploration">003924</idno><idno type="wicri:Area/France/Extraction">000404</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Pharmacology, Clinical Investigation Center, Toulouse University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Department of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-05">2005-05</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="523">523</biblScope><biblScope unit="page" to="539">539</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">44383AF5586D45FB307F9631FBBDF0A5850E2639</idno><idno type="DOI">10.1002/mds.20464</idno><idno type="ArticleID">MDS20464</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine</term><term>Amantadine (therapeutic use)</term><term>Amine oxidase (flavin-containing)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Apomorphine (therapeutic use)</term><term>Benzophenones (therapeutic use)</term><term>Benzothiazoles</term><term>Bromocriptine (therapeutic use)</term><term>COMT inhibitors</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Deep Brain Stimulation (methods)</term><term>Deep brain stimulation</term><term>Dihydroergocryptine (therapeutic use)</term><term>Dopamine agonist</term><term>Ergolines (therapeutic use)</term><term>Evidence-based medicine</term><term>Fetal Tissue Transplantation (methods)</term><term>Globus Pallidus (surgery)</term><term>Humans</term><term>Indans (therapeutic use)</term><term>Indoles (therapeutic use)</term><term>Levodopa</term><term>Levodopa (therapeutic use)</term><term>Lisuride (therapeutic use)</term><term>Mesencephalon (cytology)</term><term>Mesencephalon (embryology)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Nervous system diseases</term><term>Neurosurgical Procedures (methods)</term><term>Nitrophenols (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (surgery)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pergolide (therapeutic use)</term><term>Piribedil (therapeutic use)</term><term>Selegiline (therapeutic use)</term><term>Surgery</term><term>Thiazoles (therapeutic use)</term><term>Treatment</term><term>amantadine</term><term>anticholinergics</term><term>deep brain stimulation</term><term>dopamine agonists</term><term>evidence‐based medicine</term><term>levodopa</term><term>monoamine oxidase inhibitors</term><term>neurosurgery</term><term>neurotransplantation</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Benzophenones</term><term>Bromocriptine</term><term>Dihydroergocryptine</term><term>Ergolines</term><term>Indans</term><term>Indoles</term><term>Levodopa</term><term>Lisuride</term><term>Monoamine Oxidase Inhibitors</term><term>Nitrophenols</term><term>Pergolide</term><term>Piribedil</term><term>Selegiline</term><term>Thiazoles</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Benzothiazoles</term><term>Catechol O-Methyltransferase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Mesencephalon</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="embryology" xml:lang="en"><term>Mesencephalon</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Deep Brain Stimulation</term><term>Fetal Tissue Transplantation</term><term>Neurosurgical Procedures</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Globus Pallidus</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Amantadine</term><term>Amine oxidase (flavin-containing)</term><term>Chirurgie</term><term>Lévodopa</term><term>Médecine factuelle</term><term>Parkinson maladie</term><term>Stimulant dopaminergique</term><term>Stimulation cérébrale profonde</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Chirurgie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to update a previous evidence‐based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001–January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non‐Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty‐seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non‐ efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non‐efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy‐based reviews is essential. We consider a 3‐year period a reasonable time frame for published updates and are working to establish a Web‐based mechanism to update the report in an ongoing manner. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Autriche</li><li>France</li><li>Portugal</li><li>États-Unis</li></country><region><li>Illinois</li><li>Midi-Pyrénées</li><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></region></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country><country name="France"><noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></noRegion></country><country name="Portugal"><noRegion><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000404 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000404 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:44383AF5586D45FB307F9631FBBDF0A5850E2639
|texte= Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
}}
| This area was generated with Dilib version V0.6.23. |  |